Lifitegrast ophthalmic solution is the first in a new class of drugs called lymphocyte function–associated antigen 1 (LFA-1) antagonists to receive FDA approval for treating the signs and symptoms of dry eye disease in adults.
Marketed as Xiidra, the drug was evaluated in more than 1000 patients in 4 trials. Patients were randomized to receive the LFA-1 antagonist or placebo eye drops, used twice daily for 12 weeks. Trial participants were aged 19 to 97 years and 76% were female. The findings showed that patients who received the LFA-1 antagonist had greater improvement in both the signs and symptoms of eye dryness compared with patients in the placebo group (http://bit.ly/29toDTi).
Voelker R. Relief From Dry Eye Disease. JAMA. 2016;316(9):918. doi:10.1001/jama.2016.11454